Related Experiment Videos
Binding specificities and affinities of egf domains for ErbB receptors
J T Jones1, R W Akita, M X Sliwkowski
1Genentech, Inc., Department of Molecular Oncology, South San Francisco, CA 94080, USA.
Abstract:
ErbB receptor activation is a complex process and is dependent upon the type and number of receptors expressed on a given cell. Previous studies with defined combinations of ErbB receptors expressed in mammalian cells have helped elucidate specific biological responses for many of the recognized gene products that serve as ligands for these receptors. However, no study has examined the binding of these ligands in a defined experimental system. To address this issue, the relative binding affinities of the egf domains of eleven ErbB ligands were measured on six ErbB receptor combinations using a soluble receptor-ligand binding format. The ErbB2/4 heterodimer was shown to bind all ligands tested with moderate to very high affinity. In contrast, ErbB3 showed much more restrictive ligand binding specificity and measurable binding was observed only with heregulin, neuregulin2beta, epiregulin and the synthetic heregulin/egf chimera, biregulin. These studies also revealed that ErbB2 preferentially enhances ligand binding to ErbB3 or ErbB4 and to a lesser degree to ErbB1.
Insights
This study measured ErbB ligand binding affinities across various ErbB receptor combinations. ErbB2/4 showed broad ligand binding, while ErbB3 exhibited specific binding, with ErbB2 enhancing ligand interactions.
Area of Science:
- Cellular signaling pathways
- Receptor-ligand interactions
- Molecular biology
Background:
- ErbB receptor activation is crucial for cell function and depends on receptor type and number.
- Previous research explored ErbB ligand-receptor interactions but lacked a defined system for direct binding affinity measurement.
- Understanding these interactions is key to deciphering cellular responses.
Purpose of the Study:
- To quantify the relative binding affinities of eleven Epidermal Growth Factor (EGF) domain-containing ErbB ligands.
- To investigate these binding affinities across six different combinations of ErbB receptors.
- To establish a defined experimental system for direct ErbB ligand-receptor binding analysis.
Main Methods:
- Utilized a soluble receptor-ligand binding assay format.
- Measured the binding affinities of the EGF domains of eleven ErbB ligands.
- Tested these ligands against six distinct combinations of ErbB receptors (ErbB1, ErbB2, ErbB3, ErbB4).
Main Results:
- The ErbB2/ErbB4 heterodimer demonstrated moderate to very high affinity binding for all tested ligands.
- ErbB3 displayed restricted ligand binding specificity, with measurable binding only to heregulin, neuregulin2beta, epiregulin, and biregulin.
- ErbB2 was found to preferentially enhance ligand binding to ErbB3 and ErbB4, and to a lesser extent, ErbB1.
Conclusions:
- ErbB receptor heterodimerization significantly influences ligand binding specificity and affinity.
- ErbB2 plays a critical role in modulating ligand interactions with other ErbB receptors, particularly ErbB3 and ErbB4.
- This study provides a quantitative framework for understanding ErbB receptor-ligand dynamics in a defined system.